See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Trade War
Donald Trump
Stock Markets
Social Media
US Economy
Artificial Intelligence
Natural Disasters
Baseball
Education
European Union
Senate
Published • loading... • Updated

MC4R Agonist bremelanotide co-administered with tirzepatide meets primary endpoint

Summary by bariatricnews.net
Palatin Technologies’ BMT-801 Phase 2 obesity co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide resulted in a 4.4% reduction in weight compared to 1.6% for the placebo group (p
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
bariatricnews.netbariatricnews.net

MC4R Agonist bremelanotide co-administered with tirzepatide meets primary endpoint

Palatin Technologies’ BMT-801 Phase 2 obesity co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide resulted in a 4.4% reduction in weight compared to 1.6% for the placebo group (p

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

bariatricnews.net broke the news in on Thursday, April 3, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Obesity

Obesity

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal